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BRIEF DEFINITIVE REPORT
            Given the contribution of uncontrolled in-
fl  ammation to many human diseases, the iden-
tifi  cation of endogenous control mechanisms 
in the acute infl  ammatory response is of wide 
interest (  1  ). Classical lipid mediators such as 
the prostaglandins and leukotrienes are well 
appreciated for their important proinfl  amma-
tory roles in infl  ammation (  2  ). In recent years, 
the resolution of infl  ammation has emerged as 
an area with considerable potential to contain 
local mediators that may be useful for new 
therapeutic approaches (for reviews see refer-
ences   3, 4  ). Using an unbiased systems ap-
proach using lipidomics, proteomics, and cell 
traffi     cking to study self-resolving infl  amma-
tory exudates revealed that the termination 
of acute infl  ammation involves active biosyn-
thetic processes producing novel endogenous 
lipid mediators that are both antiinfl  ammatory 
and proresolving (  5  –  8  ). It is now clear that 
resolution of acute infl  ammation is an active 
rather than passive process, as previously un-
derstood (  9  ), generating novel potent counter-
regulatory mediators termed resolvins (Rvs) 
and protectins (for review see reference   4  ). 
  Rvs and protectins are biosynthesized by 
exudates from essential omega-3 fatty acids (e.g., 
eicosapentaenoic acid [EPA] and docosahexae-
noic acid [DHA]), and the structures are estab-
lished for key members of these families (  4  ). The 
immune regulatory actions of omega-3 fatty ac-
ids and their roles in human health and diseases 
such as cancer and neuroinfl   ammation are 
widely appreciated (  10  –  12  ). Although omega-3 
fatty acids are in wide use as dietary supplements 
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  The endogenous cellular and molecular mechanisms that control acute infl  ammation and its 
resolution are of wide interest. Using self-resolving infl  ammatory exudates and lipidomics, 
we have identifi  ed a new pathway involving biosynthesis of potent antiinfl  ammatory and 
proresolving mediators from the essential fatty acid docosahexaenoic acid (DHA) by macro-
phages (M    s). During the resolution of mouse peritonitis, exudates accumulated both 17-
hydroxydocosahexaenoic acid, a known marker of 17  S  -D series resolvin (Rv) and protectin 
biosynthesis, and 14  S  -hydroxydocosa-4  Z  ,7  Z  ,10  Z  ,12  E  ,16  Z  ,19  Z  -hexaenoic acid from endog-
enous DHA. Addition of either DHA or 14  S  -hydroperoxydocosa-4  Z  ,7  Z  ,10  Z  ,12  E  ,16  Z  ,19  Z  -
hexaenoic acid to activated M    s converted these substrates to novel dihydroxy-containing 
products that possessed potent antiinfl  ammatory and proresolving activity with a potency 
similar to resolvin E1, 5  S  ,12  R  ,18  R  -trihydroxyeicosa-6  Z  ,8  E  ,10  E  ,14  Z  ,16  E  -pentaenoic acid, 
and protectin D1, 10  R  ,17  S  -dihydroxydocosa-4  Z  ,7  Z  ,11  E  ,13  E  ,15  Z  ,19  Z  -hexaenoic acid. 
Stable isotope incorporation, intermediate trapping, and characterization of physical and 
biological properties of the products demonstrated a novel 14-lipoxygenase pathway, 
generating bioactive 7,14-dihydroxydocosa-4  Z  ,8,10,12,16  Z  ,19  Z  -hexaenoic acid, coined 
M     mediator in resolving infl  ammation (maresin), which enhances resolution. These fi  nd-
ings suggest that maresins and this new metabolome may be involved in some of the ben-
efi  cial actions of DHA and M    s in tissue homeostasis, infl  ammation resolution, wound 
healing, and host defense. 
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  These two LOX products were identifi  ed by characteris-
tic diagnostic ions in their respective mass spectra.   Fig. 1 B   
shows a representative spectrum of 17-HDHA formed in the 
and potential therapeutics in many diseases, including infl  amma-
tory diseases, their mechanisms and connection to infl  ammation 
remain of interest. Rvs and protectins display potent multilevel 
antiinfl  ammatory and proresolving actions (  13  ) and are mem-
bers of a new genus of endogenous mediators of resolution 
(  4  ). For example, resolvin E1, 5  S  ,12  R  ,18  R  -trihydroxyeicosa-
6  Z  ,8  E  ,10  E  ,14  Z  ,16  E  -pentaenoic acid (RvE1) is bio  synthesized 
from EPA and interacts with specifi  c receptors to control in-
fl  ammatory cells (  14, 15  ). Also,   fat-1   transgenic mice, produc-
ing higher endogenous levels of omega-3, show reduced 
infl  ammatory status and elevated levels of Rvs and protectins, 
which when administered reduce infl  ammation and stimulate 
resolution (  16  –  18  ). The main biosynthetic route with DHA 
for Rvs and protectins proceeds during resolution via a 17  S  -
hydroperoxydocosahexaenoic intermediate produced by a li-
poxygenase (LOX) mechanism. With aspirin therapy, acetylated 
cyclooxygenase-2 produces aspirin-triggered 17  R  -epimers of 
Rvs and protectins and also enhances their formation (  6  ). Ge-
netic defi  ciency or overexpression of mouse 12/15-LOX 
regulates production of Rvs and protectins, and alters their re-
sponses to both thermal injury and extent of atherosclerosis 
(  17, 18  ). 
  In this report, we present evidence for a new pathway of 
mediators operative in resolution of acute infl  ammation that 
possess potent actions with polymorphonuclear neutrophils 
(PMNs) and macrophages (M    s). Identifi   cation of these 
new mediators, coined M     mediators in resolving infl  am-
mation (maresins), provides evidence for autacoids produced 
from essential omega-3 fatty acids by a new pathway that may 
be linked to homeostasis, infl  ammation resolution, wound 
healing, and cancer. 
    RESULTS AND DISCUSSION   
  Targeted lipidomics of resolving infl  ammatory exudates 
  In view of the actions of specialized chemical mediators in 
resolution (  6, 7  ), we monitored 17-hydroxydocosahexaenoic 
acid (17-HDHA) as a biomarker of activation and conversion 
of endogenous DHA, and also used targeted lipidomics to 
query whether other pathways were operative (  Fig. 1  ).   Dur-
ing this course of peritonitis, PMNs rapidly entered, reach-
ing maximum within 12 h. As expected in this self-resolving 
system (  19  ), PMNs declined and were lost from exudates, 
thus defi  ning resolution (  Fig. 1  ). Unbiased targeted media-
tor lipidomics using liquid chromatography  –  tandem mass 
spectrometry (LC/MS/MS)  –  based analyses were performed 
with these exudates. In addition to 17  S  -hydroxydocosa-
4  Z  ,7  Z  ,10  Z  ,13  Z  ,15  E  ,19  Z  -hexaenoic acid, a marker of Rv 
and protectin biosynthesis (  6  ), endogenous DHA was con-
verted to 14  S  -hydroxydocosa-4  Z  ,7  Z  ,10  Z  ,12  E  ,16  Z  ,19  Z  -
hexaenoic acid (14  S  -HDHA). Neither product was identifi  ed 
in exudates obtained with the LOX inhibitor esculetin (  n   = 3), 
and both were substantially reduced in peritonitis lavages 
from 12/15-LOX  –  defi  cient mice (  n   = 2, d = 4). The appear-
ance of 14  S  -HDHA in this system accompanied 17-HDHA 
throughout the 72-h course, indicating that 14  S  -HDHA ac-
cumulated within the resolution phase. 
    Figure 1.         Self-resolving acute infl  ammatory exudates.   (A)  Time 
course of PMN (dashed line;   n   = 4) accumulation, resolution, and hy-
droxydocosahexaenoic acid formation during zymosan-initiated perito-
nitis. Exudates were extracted for targeted lipidomics using LC/MS/MS. 
Hydroxydocosahexaenoic acids 17-HDHA (dotted line) and 14  S -HDHA 
(continuous line) identifi  ed using MRM results are representative (  n   = 3). 
(B and C) Representative mass spectra for 17-HDHA (B) and 14  S -HDHA 
(C;   n   = 3). amu, atomic mass unit.     JEM VOL. 206, January 19, 2009  17
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material showed remarkable antiinfl  ammatory properties 
(  Fig. 3 A  ) regulating PMN entry into zymosan-induced perito-
nitis when directly compared with other omega-3 fatty acid –
  derived mediators such as neuroprotectin/protectin D1, 10  R  ,
time course, and   Fig. 1 C   shows the spectrum of 14  S  -
HDHA, as well as diagnostic ions for identifi  cation. These 
included mass-to-charge ratio (m/z) 205, 138, and 233, spe-
cifi  c for 14  S  -HDHA. The m/z 343 [M-H], and m/z 325, 
299, and 281 ions are shared between 14- and 17-HDHA 
(  Fig. 1, B and C  , insets). Both 14  S  -HDHA and 17-HDHA 
were also generated from endogenous DHA with isolated 
mouse M    s activated with Ca  2+   ionophore A  23187   (5   μ  M, 
pH 7.45,   n   = 4; representative values: 14  S  -HDHA, 325 
pg/10  6   cells, and 17-HDHA, 439 pg/10  6   cells). These results 
demonstrate that during the time course of acute infl  amma-
tion and its resolution, a sustained production of endogenous 
LOX products was present in the initial acute phase at 2  –  4 h 
that accumulated during resolution with the highest levels of 
14  S  -HDHA   >   17-HDHA at 72 h. 
  We reasoned that 14  S  -HDHA might be a marker re-
fl  ecting activation of a novel DHA (C22:6) carbon 14  – 
lipoxygenation pathway. This could lead to production of 
bioactive mediators via DHA, because monohydroxy prod-
ucts of polyunsaturated fatty acids are biomarkers of path-
ways leading to potent bioactive molecules, as in the case 
of 17-HDHA and 17-HpDHA, precursors to Rvs and pro-
tectins (  6, 20, 21  ). Also, 5-hydroxyeicosatetraenoic acid is a 
well-appreciated marker of arachidonic acid conversion to 
leukotrienes (  2  ). To this end, resident peritoneal M    s were 
isolated (  Fig. 2 A  , FACS inset), containing     85  –  90% M    s 
and 10  –  15% lymphocytes, and 14  S  -hydroperoxydocosa-
4  Z  ,7  Z  ,10  Z  ,12  E  ,16  Z  ,19  Z  -hexaenoic acid (14  S  -HpDHA) was 
prepared via biogenic synthesis and incubated with these cells 
to determine whether it was a precursor to new bioactive 
products.   14  S  -HpDHA was isolated from 12-LOX incubated 
with HPLC-purifi  ed DHA (  n   = 7) and was   >  98%   S   confi  gu-
ration determined by chiral LC/MS/MS. Both 14  S  -HpDHA 
(10   μ  M) and DHA (10   μ  M) were converted by resident M    s 
to new products identifi  ed via LC/MS/MS-based mediator 
lipidomics (  Fig. 2 A  ) labeled I and II. Each had conjugated 
triene-containing UV chromophores, chromatographic be-
havior, and mass spectra consistent with 7,14-dihydroxy  –
  containing products with a C22 backbone originating from 
DHA. Both gave essentially the same mass spectrum yet dif-
ferent retention times, indicating that they were very likely 
isomers (  Fig. 2, B and C  ). These were isolated and subject to 
gas chromatography  –  mass spectrometry (GC-MS) to further 
identify and confi   rm fragment assignments and positional 
sites of oxygenation, e.g., carbon positions of alcohol groups. 
GC-MS analyses confi  rmed assigned ions from LC/MS/MS 
and were consistent with 7,14-dihydroxy  –  containing prod-
ucts biosynthesized from DHA (  Table I  ).   Isolated human 
M    s incubated with 14  S  -HpDHA also gave the novel 7,14-
dihydroxy  –  containing product and matched the compound 
from mouse M    s (  n   = 3). 
  Novel antiinfl  ammatory and proresolving mediators 
  In parallel with these determinations, materials obtained from 
mouse M    s were assessed for potential bioactivity after ex-
traction and C18 solid-phase chromatography. M    -derived 
    Figure 2.         M    s generate novel products.   (A) Mouse-resident M   s 
(5   ×   10 6   cells/ml) incubated with DHA or 14  S  -HpDHA showing targeted 
LC/MS/MS-based mediator lipidomics. Selected ion chromatogram (m/z 
359/250) of 7,14-diHDHA (II) and its transconjugated isomer (I) is shown. 
Selected ion chromatogram (dashed overlay; m/z 359/250) shows double 
dioxygenation product 7  S ,14 S  -diHDHA. (inset) FACS plot of isolated resi-
dent M    s. (B and C) Lipid mediator lipidomics. (B) Mass spectra for 7,14-
diHDHA (m/z 359; B) and corresponding isomer (C). See inset and Results 
for diagnostic ions (  n   = 3). amu, atomic mass unit.     18 NOVEL MEDIATORS IN RESOLUTION   | Serhan et al. 
did not coelute with M    -derived products beneath labels 
I and II. This double dioxygenation product at a 0.1-ng 
dose per mouse reduced PMN infi   ltration in zymosan-
induced peritonitis but appeared to be less potent than the 
M    -isolated material (  Fig. 3 B  ). Thus, the results in   Fig. 3   
clearly demonstrate potent bioactions of the novel 7,14-
dihydroxy  –  containing product HPLC purifi   ed from resi-
dent M     incubations with zymosan and 14  S  -HpDHA. 
  Further experiments were performed to isolate material be-
neath peaks I and II (  Fig. 2 A  ) and determine whether com-
pound I is an isomer of II. Subjecting the isolated compounds 
to isomerization conditions (  22  ) demonstrated that compound 
II likely contained a cis double bond  –  containing triene struc-
ture sensitive to conversion to an all-trans  –  containing conju-
gated triene (i.e., 8  E  ,10  E  ,12  E  ) isomer I in bench and work-
up conditions. In view of   18  O incorporation and epoxide 
trapping, it is likely that the isomer I peak also contained   R/S   
racemates at carbon 7. Further RP-HPLC purifi  cation of the 
7,14-dihydroxy  –  containing product from M    s was performed 
17  S  -dihydroxydocosa-4  Z  ,7  Z  ,11  E  ,13  E  ,15  Z  ,19  Z  -hexaenoic 
acid (PD1) (  20  ) and RvE1 (  5, 6, 14  ).   Thus, these fi  ndings sug-
gested that within M     isolates obtained from cells incubated 
with 14  S  -HpDHA, potent bioactive materials were biosyn-
thesized from this precursor that regulated PMNs, preventing 
their infi  ltration. These substances were likely to be very po-
tent because only nanogram quantities given per mouse elic-
ited antiinfl  ammatory actions. 
  Given the ability of DHA to serve as a substrate for 
LOX forming both double dioxygenation products related 
to PD1 as well as the carbon 17  –  hydroperoxide  –  containing 
precursor of epoxide (  20  ), we reasoned that 14  S  -HpDHA 
might also be a substrate for double dioxygenation. This in  deed 
proved to be the case: sequential actions of 12-LOX and 
5-LOX with DHA generated 7  S  ,14  S  -dihydroxydocosa-
4  Z  ,8  E  ,10  Z  ,12  E  ,16  Z  ,19  Z  -hexaenoic acid (7  S  ,14  S  -diHDHA; 
  n   = 5;   Fig. 2  , dotted profi  le; and   Table I  ). This is likely 
an isomer of the M    -isolated material (  Figs. 2 and 3  ), be-
cause this reference compound (  Fig. 2 A  , dotted curve) 
    Table I.        Structures and LC-MS and GC-MS fragmentation for novel 14 series compounds identifi  ed using mediator-based lipidomics 
Compound LC retention  
  time (min)
LC-MS  
  major fragment ions    a   
GC-MS  
  major fragment ions    b   
C value UV       max      c   
 
14  S  -HDHA
17.1 343 (M-H), 325, 299, 281,  
  233, 205, 189, 161
430 (M), 321, 219, 211,  
  129, 121, 109
24.2 237
MaR1
12.2 359 (M-H), 341, 323, 315,  
  297, 279, 250, 221, 177,  
  161, 141, 123, 113
487 (M-31), 428, 413,  
  409, 338, 307, 229,217,  
  211, 139, 127, 121, 109
24.2, 26 270
7  S  ,14  S  -dihydroxy (double dioxygenation product)
12.6 359 (M-H), 341, 323, 315,  
  297, 279, 250, 221, 177,  
  161, 141, 123, 113
409, 229, 217, 211,139,  
  127, 121, 109
24.1 270
(minor) 4,14-dihydroxy
13.6 359 (M-H), 341, 323,315,  
  297, 279, 249, 221, 203,  
  177, 101
487 (M-31), 428, 413,  
  409, 338, 307, 217, 211,  
  121, 109
24.2     245
13,14-dihydroxy
  –   –  487 (M-31), 428, 413,  
  409, 338, 313, 307,223,  
  217, 211, 205, 121, 109
24.2, 25     270
Stereochemistries shown are tentative assignments. Double-bond geometries are shown in likely confi  gurations based on proposed biosynthetic pathways.
  a  LC-MS/MS analysis was performed with an Agilent Technologies 1100 series HPLC system coupled to an Applied Biosystems 3200 QTRAP linear ion trap quadrupole mass 
spectrometer equipped with an Agilent Technologies Eclipse Plus C18 column (4.6 mm   ×   50 mm   ×   1.8   μ  m). The mobile phase consisted of methanol/water/acetic acid 
(60:40:0.01, vol/vol/vol) and was ramped to 80:20:0.01 over 7.5 min and to 95:5:0.01 over the next 4.5 min at a fl  ow rate of 400   μ  l/min. The fl  ow rate was decreased to 200   μ  l/
min for 3 min and returned to 400   μ  l/min, and the mobile phase was ramped up over the next 6 min to 100:0:0.01 before returning to 60:40:0.01.
  b  GC-MS analysis was performed with an HP6890 system (Agilent Technologies) equipped with an HP5973N mass detector. An HP-5MS column (30m   ×   0.25 mm   ×   0.25   μ  m) 
was used with a temperature program; the initial temperature was 150  °  C, followed by 230  °  C for 8 min and 280  °  C for 10 min with a helium fl  ow rate of 1 ml/min. 
Trimethylsilyl derivatives were prepared after treatment with diazomethane.
  c  Spectra were recorded in methanol using an Agilent Technologies 4682 UV-Vis spectrophotometer or an Agilent Technologies 1100 series diode-array detector.JEM VOL. 206, January 19, 2009  19
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uct (7  S  ,14  S  -diHDHA) was active but less potent than the 
new product isolated from M    s. Thus, given its potent ac-
tions and novel structure, the M     product was denoted ma-
resin 1 (MaR1). 
  Maresin biosynthetic pathway 
  We present a hypothetical scheme for the maresin pathway 
(see   Fig. 5  ). DHA is converted to 14-hydroperoxydocosa-
hexaenoic acid, likely via 12-LOX in humans, as shown in 
incubations of DHA and 12-LOX, followed by either reduc-
tion to 14  S  -HDHA and/or, via double dioxygenation (e.g., 
sequential 12-LOX  –  5-LOX), to generate 7  S  ,14  S  -diHDHA. 
In 12/15-LOX  –  defi  cient mice, 14  S  -HDHA generation in 
peritonitis was reduced   >  95%. The key 14  S-  hydroperoxide 
to assess its actions. The results in   Fig. 3 C   demonstrate that at 
doses as low as 0.2 ng/mouse, the new compound potently re-
duced infi  ltration of PMNs into sites of infl  ammation. 
  M    -enhanced phagocytosis 
  A key feature of a proresolving mediator, in addition to limit-
ing PMN entry, is the dual action of stimulating M     uptake 
of apoptotic PMNs and/or zymosan to stimulate resolution 
and microbial clearance (  4, 13, 23  ). We determined whether 
the new M    -derived compound enhanced phagocytosis and 
compared it with RvE1, PD1, and an eicosanoid, prostaglan-
din E  2   (PGE  2  ;   Fig. 3 D  , inset). RvE1 and PD1 are potent en-
hancers of M     phagocytosis at concentrations as low as 1 nM 
(  13  ). For direct comparison, the double dioxygenation prod-
    Figure 3.         Antiinfl  ammatory and proresolving novel M     products.   (A) Reduction in PMN in peritonitis. Activity in methyl formate fractions from 
C18 extraction of isolated M    s and 20 ng/mouse of M     products isolated with RP-HPLC, 20 ng/mouse PD1, or 20 ng/mouse RvE1. Results are expressed 
as exudate PMN means   ±   SEM (  n   = 3; *, P   <   0.05 compared with zymosan plus vehicle). (B) Differential PMN versus monocyte actions. Mice were injected 
with 0.1 ng/mouse of the double dioxygenation product, 0.1 ng/mouse of M     isolate, or vehicle alone (as in A), followed by i.p injection of 1 mg zymosan 
to evoke peritonitis. After 2 h, leukocytes were enumerated (black bar, PMNs; hatched bar, mononuclear cells). Results are means   ±   SEM (  n   = 3; *, P   <   0.05 
compared with zymosan plus vehicle;   †  , P   <   0.05 for double dioxygenation vs. M     isolate). (C) Reduction in peritonitis showing dose response. M     prod-
uct isolated after HPLC isolation was injected i.v.     2 min before i.p. zymosan. Results are means   ±   SEM (  n   = 3; *, P   <   0.05 compared with zymosan plus 
vehicle). (D) MaR1 enhances phagocytosis. M    s (24-well plate, 10  5   cells/well) were exposed to the indicated concentrations for 15 min followed by FITC-
labeled zymosan for 30 min at 37  °  C. Results are means   ±   SEM expressed as the percent increase above vehicle (  n   = 3; *, P   <   0.05 compared with vehicle;   †  , 
P   <   0.05 for double dioxygenation vs. MaR1). The closed diamond represents MaR1, and the closed square represents the double dioxygenation product 
7  S ,14 S  -diHDHA. (inset) Comparison of MaR1 with other mediators (1 nM).     20 NOVEL MEDIATORS IN RESOLUTION   | Serhan et al. 
m/z 251, 223 and 250, 221, respectively (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20081880/DC1). 
Collectively, these results provide support for the biosynthesis 
of a 13(14) epoxide intermediate by M    s from 14  S  -HpDHA 
that is enzymatically converted to the potent bioactive 7,
14-dihydroxydocosa-4  Z  ,8,10,12,16  Z  ,19  Z  -hexaenoic acid 
MaR1 (  Fig. 5  ). 
  DHA (C22:6) is an essential fatty acid and member of the 
omega-3 family of fatty acids, which are in high levels in 
marine oils. It is essential for mammalian systems in that it is 
not biosynthesized de novo and is therefore a nutritional re-
quirement (  10, 11, 21  ). In this report, we identifi  ed a novel 
pathway during resolution that converts DHA to new, po-
tent bioactive products. This new pathway was identifi  ed 
using targeted mediator lipidomics of exudates from mouse 
peritonitis and was demonstrated with both mouse and hu-
man M    s. Parallel biofunction and spectral analyses con-
fi  rmed the new structures as 7,14-dihydroxy  –  containing 
products biosynthesized from DHA. One of the novel prod-
ucts characterized, MaR1, proved to be a potent mediator, 
stopping PMN infi  ltration and stimulating M     phagocyto-
sis. An isomer of MaR1, 7  S  ,14  S  -diHDHA, was less potent, 
indicating stereoselective actions in vitro and in vivo. These 
antiinfl  ammatory and proresolving actions were evident in 
nanogram range both in vitro and in vivo, suggesting that 
this new mediator pathway could play a key role in regulat-
ing catabasis or the return of tissues from the infl  ammatory 
state to homeostasis (  8, 13  ). 
  The new compounds isolated from M    s showed distinct 
and separate actions on PMNs compared with mononuclear 
cells, such as those recently identifi  ed for multifunctional 
mediators. Specifi  cally, to expedite resolution, members of 
this new genus of endogenous mediators carry multilevel ac-
tions limiting further PMN accumulation at tissue sites and 
stimulate clearance by enhancing M     nonphlogistic phago-
cytosis (  4, 23  ). This type of selectivity places a spatial and 
temporal as well as a functional separation between these 
new mediators from, e.g., leukotrienes, which stimulate pro-
infl  ammatory responses. 
  When compared with RvE1 derived from EPA and 
PD1/NPD1 from DHA that carries alcohol groups at car-
bons 10 and 17 (  6, 7, 20, 21  ), MaR1 proved to be of compa-
rable potency (  Fig. 3  ). In contrast, PGE  2   did not enhance 
phagocytosis, a fi  nding consistent with PGE  2   and PGD  2   spe-
cifi  cally reducing M     phagocytosis of apoptotic cells (  24  ). 
Although D and E series Rvs as well as PD1 share proresolv-
ing and antiinfl  ammatory actions for the genus, each mem-
ber acts at specific receptors (  4, 14  ) and, thus, given the 
stereospecifi  c actions of the new pathway mediators, it is 
likely that they act on their own receptors separate from 
those for Rvs. These fi  ndings with novel chemical mediators 
suggest that enhancing M     capacity to remove apoptotic 
and necrotic cells at sites of infl  ammation and enhancing 
microbial particle containment along with down-regulating 
new PMN entry to the site may not only shorten the resolu-
tion interval (  8, 13  ) but can also protect tissues from 
intermediate is enzymatically converted to a 13(14)-epoxide  –
  containing intermediate that is then enzymatically hydro-
lyzed via a carbonium cation to bioactive 7,14  S  -diHDHA 
by creating a conjugated triene within three of the six double 
bonds. The results from   18  O isotope incorporation using 
H  2    18  O demonstrated that   >  75% of the oxygen at the carbon 
7 position was derived from H  2  O (see Supplemental materials 
and methods and Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20081880/DC1) and not from molec-
ular oxygen, as would have been the case if this carbon 7 
position alcohol group was generated by double lipoxygen-
ation mechanism (compare with reference   20  ). In parallel, 
alcohol trapping with excess acidic methanol was performed 
with isolated M    s that gave the methoxy-trapping product 
7-methoxy-14-hydroxydocosa-4  Z  ,8,10,12,16  Z  ,19  Z  -hexaenoic 
acid, identifi  ed using LC/MS/MS targeted profi  ling. Its MS  2   
spectrum showed ions consistent with acid-assisted attack at 
the carbon 7 position and addition of the methoxy, giving 
the MS  2   spectrum of m/z 373 at 10.2 min (  Fig. 4  , inset for 
ion assignments; and   Fig. 5  ).   It is also possible that a methoxy 
addition could have occurred at the carbon 13 position that 
could give essentially the same ions in MS  2  . It is more likely 
that methoxy addition was at carbon 7, because it is the least 
sterically hindered end of the conjugated carbonium cation. 
  To provide further confi  rmation of the maresin pathway 
and biosynthetic scheme, isolated mouse M    s (15.5   ×   10  6   
cells/3 ml, 37  °  C, 30 min) were incubated with zymosan and 
10   μ  M of deuterium-labeled DHA-d  5   containing fi  ve deu-
terium atoms at the 21, 21, 22, 22, and 22 carbon positions. 
M    s converted DHA-d  5   to 14  S  -HDHA-d  5  , with diagnostic 
ions in its mass spectrum at m/z 348, 330, 304, 286, and 205, as 
well as further evidence for the 7,14  S  -dihydroxy  –  containing 
product. The dihydroxy structure carried d  5  , from precursor, 
and was confi  rmed with ions at m/z 364, 346, 320, and 302, 
and the hydroxy groups  ’   7 and 14 positions supported by 
    Figure 4.         Identifi  cation of methoxy-trapping product from M    s.   
MS/MS spectrum of m/z 373 product at 10.2 min. (inset) Extracted ion chro-
matogram of m/z 373  →  263 and deduced structure. amu, atomic mass unit.     JEM VOL. 206, January 19, 2009  21
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identifi  ed in many systems, it remained to be determined that 
it can serve as a marker of DHA conversion to novel bioac-
tive mediators. It should be noted that, in addition to 14  S  -
HDHA production by cells with 12-LOX, human 15-LOX 
can also contribute to this 14-LOX pathway because M    s 
and other human cells possess a prominent 12-LOX and 15-
LOX (  2, 10, 18  ), and 14  S  -HDHA was essentially absent in 
12/15-LOX  –  defi  cient mice. Given the importance of plate-
let 12-LOX in transcellular biosynthesis of lipid mediators 
(  4  ), it is likely that cell  –  cell interactions can also contribute to 
biosynthesis of maresins and related products. 
  Although marine omega-3 fatty acid supplements are in 
wide use in animals and humans because they are believed to 
possess therapeutic actions, convincing evidence from clinical 
trials supporting their actions in treating infl  ammatory disorders 
and reducing cancer risk are not without criticism (  29  –  31  ). 
Possible sources of variation in their actions in clinical studies 
are (a) the very high doses used (milligram to gram doses), (b) 
the absence of appropriate biomarkers of omega-3 fatty acid 
utilization, and (c) specifi  c mediator functions evoked in pico- 
to nanogram range. Thus, the new pathways and bioactive ma-
resins documented in this report, along with Rvs, protectins, 
and related functional metabolome, might provide a new means 
to mark the impact of essential omega-3 fatty acids in health and 
disease, as well as provide new therapeutic approaches. 
unwanted tissue injury damage and oxidative stress that can 
accompany infl  ammation and infection. 
  We also found that the epoxide intermediate can undergo 
non  enzymatic hydrolysis to give 7  R/S  ,14  S  -dihydroxy  –
  containing products (which appear to coelute in this LC sys-
tem) and corresponding vicinal diol, namely 13,14-diHDHA 
(which was isolated and identifi  ed; see   Fig. 5  ,   Table I  , and 
Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20081880/DC1). The proposed biosynthetic sequence is 
also supported by results from   18  O incorporation and deute-
rium (d  5  )-labeled tracking from d  5  -DHA to d  5  -labeled ma-
resin pathway products. Collectively, these results provide 
evidence for a highly effi   cient pathway in isolated resident 
M    s for the biosynthesis of potent new chemical mediators 
via 14-lipoxygenation of DHA and subsequent enzymatic 
steps (  Fig. 5  ). We also identifi  ed 4,14-di-HDHA (  Table I  ), a 
likely product of 5-LOX and 12-LOX interactions, as well as 
two other new products from DHA generated by M    s, a 
13(14)-epoxy-alcohol  –  containing docosanoid and 4  S  ,13,14  S  -
trihydroxydocosa-5,7,9,11,16  Z  ,19  Z  -hexaenoic acid (their 
bio  synthesis and actions will be reported separately). 
  The 14  S  -HDHA via arachidonate 12-LOX was fi  rst 
identifi  ed in the gills of fi  sh (  25  ) and in human platelets (  26  ), 
neural systems (  27  ), and many other mammalian and inverte-
brate marine organisms (  28  ). Thus, although 14  S  -HDHA was 
    Figure 5.         Biosynthetic scheme proposed for MaR1 and related products.   Stereochemistries and double-bond geometries of the new dihydroxy-
containing mediators are tentative assignments and depicted in likely confi  gurations based on biogenic synthesis, trapping, and labeling (see Results).     22 NOVEL MEDIATORS IN RESOLUTION   | Serhan et al. 
pair 359.2/250.2 was used to identify 7,14-dihydroxy  –  containing products. 
Criteria for matching retention time and greater than or equal to six diagnostic 
ions to those of synthetic references were used for identifi  cation (  32  ). Quanti-
tation was performed using calibration curves constructed for each compound, 
and recoveries were monitored using added deuterated internal standards. 
  Mouse peritonitis and phagocytosis.     The 7,14-dihydroxy  –  containing 
products were isolated from methyl formate fractions obtained from mouse 
M    s via RP-HPLC (Agilent Technologies 1100 series) using a Beckman 
Coulter C18 column (250 mm   ×   10 mm   ×   5   μ  m) and methanol/water (65:35, 
vol/vol) ramped to 85:15 for 30 min. Their actions were assessed in mouse 
zymosan A  –  induced peritonitis (  19  ). Peritonitis was initiated by i.p. adminis-
tration of 1 mg zymosan A in 1 ml of sterile saline, and each compound was 
administered i.v. 5 min before zymosan. At 2 h, mice were killed, and perito-
neal exudates were harvested (5 ml DPBS      /      without calcium and magne-
sium), identifi  ed, and enumerated by light microscopy and FACS. Resident 
M    s were identifi  ed by FACS (  8  ). To assess proresolving actions, peritoneal 
M    s (24-well plate, 10  5   cells/well) from naive mice were incubated with each 
compound (15 min, pH 7.45), followed by the addition of FITC-labeled zy-
mosan A for 30 min at 37  °  C. Trypan blue was used to quench extracellular 
zymosan particles for 1 min at 37  °  C, followed by DPBS  +/+   (pH 7.45), and 
phagocytosis was quantifi  ed using a Victor  3   (PerkinElmer). 
  Statistical analysis.     Results are expressed as means   ±   SEM. Statistical sig-
nifi  cance was determined using a two-tailed Student  ’  s   t   test. 
  Online supplemental material.    Fig. S1 shows the MS-MS spectrum of the 
novel product obtained with H  2    18  O and M     incubations. Fig. S2 is the rep-
resentative mass spectrum of d  5  -MaR1 from M     incubation with d  5  -DHA. 
Fig. S3 is the GC-MS spectrum obtained for the 13,14-dihydroxy vicinal diol 
from DHA and M    s. This product derivative was obtained after treatment 
with diazomethane and BSTFA to give the methyl ester, OTMS deriva-
tive. Supplemental materials and methods describes human M     incubations, 
GC-MS analysis, and chiral HPLC-MS/MS. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20081880/DC1. 
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